Log in

e-Therapeutics Share Price, Forecast & Analysis (LON:ETX)

GBX 3.17
0.00 (0.00 %)
(As of 11/15/2019 02:15 AM ET)
Today's Range
3.14
Now: GBX 3.17
3.17
50-Day Range
2.33
MA: GBX 2.91
3.65
52-Week Range
1.25
Now: GBX 3.17
7.25
Volume1.34 million shs
Average Volume54,267 shs
Market Capitalization£8.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, and Novo Nordisk. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1993-880000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£232,000.00
Cash FlowGBX 1.90 per share
Book ValueGBX 2.10 per share

Profitability

Miscellaneous

Employees18
Market Cap£8.53 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ETX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter.


e-Therapeutics (LON:ETX) Frequently Asked Questions

What is e-Therapeutics' stock symbol?

e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."

How were e-Therapeutics' earnings last quarter?

e-Therapeutics plc (LON:ETX) issued its quarterly earnings results on Tuesday, March, 27th. The company reported ($2.00) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($2.10) by $0.10. View e-Therapeutics' Earnings History.

Has e-Therapeutics been receiving favorable news coverage?

Press coverage about ETX stock has trended somewhat negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. e-Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for e-Therapeutics.

Who are some of e-Therapeutics' key competitors?

What other stocks do shareholders of e-Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other e-Therapeutics investors own include Sound Energy (SOU), Radware (RDWR), Bazaarvoice (BV), Starcom (STAR), Quarto Group (QRT), Oxford BioMedica (OXB), IP Group (IPO), Gulf Keystone Petroleum (GKP), Collagen Solutions (COS) and Bushveld Minerals (BMN).

Who are e-Therapeutics' key executives?

e-Therapeutics' management team includes the folowing people:
  • Dr. Raymond Barlow, CEO & Director (Age 50)
  • Mr. Steven Medlicott, CFO, Fin. Director & Exec. Director (Age 54)
  • Mr. Jonny Wray, Head of Discovery Informatics
  • Mr. Colin Stubberfield, Head of Drug Discovery
  • Mr. Alan Whitmore, Head of Discovery Biology

How do I buy shares of e-Therapeutics?

Shares of ETX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is e-Therapeutics' stock price today?

One share of ETX stock can currently be purchased for approximately GBX 3.17.

How big of a company is e-Therapeutics?

e-Therapeutics has a market capitalization of £8.53 million and generates £232,000.00 in revenue each year. e-Therapeutics employs 18 workers across the globe.View Additional Information About e-Therapeutics.

What is e-Therapeutics' official website?

The official website for e-Therapeutics is http://www.etherapeutics.co.uk/.

How can I contact e-Therapeutics?

e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000.


MarketBeat Community Rating for e-Therapeutics (LON ETX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics and other stocks. Vote "Outperform" if you believe ETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel